ImmunityBio: Despite Anktiva's Clinical Promise, This Remains A Difficult Investment

Syndax Looks Tantalizing, But Looks Can Be Deceptive

Benitec Biopharma: Early Positive Data, Small Target Market, Little Competition

Cartesian Therapeutics: Need To Wait For More Data For Its Novel mRNA Therapies

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again

XOMA Royalty Corporation: High-Risk Royalty Aggregator Best Avoided

Arcus: Excellent Pipeline And Collaborations, Cash Runway

aTyr Pharma: Interesting Drug, Difficult Target Market

Wave Life Sciences Is A Buy On Pipeline Prospects

Enliven's Early Data Stands Out From Peers

Those Derisked Baby Bonds Of Harrow, Inc.

Silence Therapeutics: Simply No Match For Its Orally Dosed Rival (Downgrade)

Structure Therapeutics: Competitive Data Is Emerging

Mesoblast After Approval: Stock Is Buoyant Now, But Unpredictable Overall

Ocular Is Now Thoroughly Derisked

Telix Pharmaceuticals: Australian Company And A Solid Recent U.S. IPO

Mirum Pharmaceuticals: Buy At Dips For Volixibat Potential

Apellis: Saved By The October Data

Scholar Rock: Good Company, But This Ship Has Sailed

Vera Therapeutics: Strong Data In IgAN, But We May Be Too Late

Travere Therapeutics: Cautiously Bullish Based On Improving Revenue

Soleno Therapeutics: PDUFA Extension May Be An Opportunity, But Not For Me

Harrow: The Triesence Relaunch

Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable

Immunome: A Recently Acquired Lead Asset And A Small Market